Novo Nordisk has both internal research and external alliances pursuing new drugs that could shape the next generation of metabolic medicines. The pharmaceutical giant’s latest move is a partnership with Replicate Biosciences , a clinical-stage startup whose work focuses on an emerging type of RNA therapy.

The agreement announced Thursday calls for the companies to collaborate on undisclosed targets for obesity, type 2 diabetes, and other cardiometabolic diseases. Novo Nordisk receives an exclusive, worldwide license to use Replicate’s technology platform to develop and commercialize the lead programs.

San Diego-based Replicate specializes in self-replicating RNA, or srRNA. This type of RNA works by replicating itself inside the cells of a patient. These RNA instruct the cells to conti

See Full Page